These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28320519)

  • 1. Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab.
    Nerrant E; Thouvenot E; Castelnovo G
    Rev Neurol (Paris); 2017 Mar; 173(3):175-176. PubMed ID: 28320519
    [No Abstract]   [Full Text] [Related]  

  • 2. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
    Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
    Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
    Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
    Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
    Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab].
    Eichau S; Lopez-Ruiz R; Ruiz-Pena JL; Paramo MD; Navarro-Mascarell G; Izquierdo G
    Rev Neurol; 2018 Jun; 66(11):395-396. PubMed ID: 29790573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    Gao J; Jones J; Damato EM; Coles A
    J Neurol; 2019 Jun; 266(6):1539-1540. PubMed ID: 30895387
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
    Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
    [No Abstract]   [Full Text] [Related]  

  • 9. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
    Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
    Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Ahrabian D; Neill L; Bell R; Leary SM
    Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracerebral haemorrhage during alemtuzumab administration.
    Azevedo CJ; Kutz C; Dix A; Boster A; Sanossian N; Kaplan J
    Lancet Neurol; 2019 Apr; 18(4):329-331. PubMed ID: 30777657
    [No Abstract]   [Full Text] [Related]  

  • 13. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
    Metz I; Rieckmann P; Kallmann BA; Brück W
    Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
    [No Abstract]   [Full Text] [Related]  

  • 14. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
    Saarela M; Senthil K; Jones J; Tienari PJ; Soilu-Hänninen M; Airas L; Coles A; Saarinen JT
    Neurology; 2018 May; 90(18):849-851. PubMed ID: 29602914
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis.
    Penkert H; Delbridge C; Wantia N; Wiestler B; Korn T
    JAMA Neurol; 2016 Jun; 73(6):757-9. PubMed ID: 27043129
    [No Abstract]   [Full Text] [Related]  

  • 17. Alemtuzumab for the treatment of multiple sclerosis.
    Evan JR; Bozkurt SB; Thomas NC; Bagnato F
    Expert Opin Biol Ther; 2018 Mar; 18(3):323-334. PubMed ID: 29309202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient.
    Baroncini D; Annovazzi P; Guaschino C; Minonzio G; Hametner S; Stadelmann C; Comi G; Ghezzi A; Zaffaroni M
    Mult Scler Relat Disord; 2020 Jun; 41():102061. PubMed ID: 32203930
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS.
    Pfeuffer S; Beuker C; Ruck T; Lenze F; Wiendl H; Melzer N; Meuth SG
    Neurology; 2016 Nov; 87(22):2380-2381. PubMed ID: 27794114
    [No Abstract]   [Full Text] [Related]  

  • 20. Alemtuzumab as Treatment for Multiple Sclerosis.
    Katsavos S; Coles A
    Cold Spring Harb Perspect Med; 2018 Oct; 8(10):. PubMed ID: 29500306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.